PDF(Pubmed)
Abstract：
Cancer involves a series of diseases where cellular growth is not controlled. Cancer is a leading cause of death worldwide, and the burden of cancer incidence and mortality is rapidly growing, mainly in developing countries. Many drugs are currently used, from chemotherapeutic agents to immunotherapy, among others, along with organ transplantation. Treatments can cause severe side effects, including remission and progression of the disease with serious consequences. Increased glycolytic activity is characteristic of cancer cells. Triosephosphate isomerase is essential for net ATP production in the glycolytic pathway. Notably, some post-translational events have been described that occur in human triosephosphate isomerase in which functional and structural alterations are provoked. This is considered a window of opportunity, given the differences that may exist between cancer cells and their counterpart in normal cells concerning the glycolytic enzymes. Here, we provide elements that bring out the potential of triosephosphate isomerase, under post-translational modifications, to be considered an efficacious target for treating cancer.
摘要：
癌症涉及一系列细胞生长不受控制的疾病。癌症是全世界死亡的主要原因,癌症发病率和死亡率的负担正在迅速增加，主要在发展中国家。目前使用的药物很多，从化疗药物到免疫疗法，其中,还有器官移植.治疗会引起严重的副作用，包括疾病的缓解和进展，并带来严重后果。糖酵解活性增加是癌细胞的特征。磷酸三糖异构酶对于糖酵解途径中的净ATP产生是必需的。值得注意的是,已经描述了一些在人磷酸丙糖异构酶中发生的翻译后事件，其中引起功能和结构改变。这被认为是一个机会之窗,鉴于癌细胞和正常细胞中它们的对应物之间可能存在的关于糖酵解酶的差异。这里,我们提供了能够发挥磷酸丙糖异构酶潜力的元素，在翻译后修饰下，被认为是治疗癌症的有效靶标。
